iPSC-derived CAR-NK cell therapy - Cell Inspire Bio
Alternative Names: anti-GPRC5D CAR-iNK - Cell Inspire Bio; CAR-iPSC-NK - Cell Inspire BioLatest Information Update: 22 Jan 2024
At a glance
- Originator Cell Inspire Bio
- Class Antineoplastics; CAR-NK cell therapies; Gene therapies; Immunotherapies; Induced pluripotent stem cell therapies
- Mechanism of Action Immunologic cytotoxicity; Natural killer cell replacements
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- Preclinical Multiple myeloma
Most Recent Events
- 22 Jan 2024 Cell Inspire Bio has patent protection for passaging and application of human induced pluripotent stem cells in China (Cell Inspire Bio website, January 2024)
- 09 Dec 2023 Preclinical trials in Multiple myeloma in China (Parenteral) before December 2023
- 09 Dec 2023 Pharmacodynamics data from a preclinical study in Multiple myeloma presented at the 65th American Society of Hematology Annual Meeting and Exposition (ASH-Hem-2023)